A
Adrián Gadano
Researcher at Hospital Italiano de Buenos Aires
Publications - 202
Citations - 6516
Adrián Gadano is an academic researcher from Hospital Italiano de Buenos Aires. The author has contributed to research in topics: Liver transplantation & Internal medicine. The author has an hindex of 30, co-authored 174 publications receiving 5562 citations. Previous affiliations of Adrián Gadano include National Scientific and Technical Research Council.
Papers
More filters
Journal ArticleDOI
A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B
Ting-Tsung Chang,Robert G. Gish,Robert A. de Man,Adrián Gadano,Jose D. Sollano,You Chen Chao,Anna S. Lok,Kwang Hyub Han,Zachary Goodman,J. Zhu,Anne Cross,Deborah DeHertogh,R B Wilber,Richard J. Colonno,David Apelian +14 more
TL;DR: Among patients with HBeAg-positive chronic hepatitis B, the rates of histologic, virologic, and biochemical improvement are significantly higher with entecavir than with lamivudine, and the safety profile of the two agents is similar.
Journal Article
Clinical practice guidelines: Management of Hepatocellular Carcinoma
Nahum Méndez-Sánchez,Ezequiel Ridruejo,Angelo Alves de Mattos,Norberto C. Chávez-Tapia,Rodrigo Zapata,Raymundo Paraná,Ricardo Mastai,Edna Strauss,Luis Gonzalo Guevara-Casallas,Jorge Daruich,Adrián Gadano,Edison Roberto Parise,Misael Uribe,Nancy E. Aguilar-Olivos,Lucy Dagher,Ben Hur Ferraz-Neto,Martha Valdés-Sánchez,Juan Francisco Sánchez-Ávila +17 more
Journal ArticleDOI
Entecavir therapy for up to 96 weeks in patients with HBeAg-positive chronic hepatitis B.
Robert G. Gish,Anna S. Lok,Ting-Tsung Chang,Robert A. de Man,Adrián Gadano,Jose D. Sollano,Kwang Hyub Han,You Chen Chao,Shou-Dong Lee,Melissa Harris,Joanna Yang,Richard J. Colonno,Helena Brett-Smith +12 more
TL;DR: Entecavir treatment through 96 weeks results in continued benefit for patients with HBeAg-positive chronic hepatitis B (CHB), and the safety profile was comparable in both groups.
Journal ArticleDOI
Epidemiology and Effects of Bacterial Infections in Patients With Cirrhosis Worldwide
Salvatore Piano,Virendra Singh,Paolo Caraceni,Rakhi Maiwall,Carlo Alessandria,Javier Romaní Fernández,Elza Cotrim Soares,Dong Joon Kim,Sung Eun Kim,M. Marino,Julio Vorobioff,Rita de Cassia Ribeiro Barea,Manuela Merli,Laure Elkrief,Victor Vargas,Aleksander Krag,Shivaram Prasad Singh,Laurentius A. Lesmana,C. Toledo,Sebastián Marciano,Xavier Verhelst,Florence Wong,Nicolas M. Intagliata,Liane Rabinowich,Luis Colombato,Sang Gyune Kim,Alexander L. Gerbes,François Durand,Juan Pablo Roblero,Kalyan Ram Bhamidimarri,Thomas D. Boyer,M. V. Maevskaya,Eduardo Fassio,Hyoung Su Kim,Jae Seok Hwang,Pere Ginès,Adrián Gadano,Shiv Kumar Sarin,Paolo Angeli,Michele Bartoletti,Carlos Brodersen,Tony Bruns,Robert A. de Man,Annette Dam Fialla,Carmine Gambino,Vikas Gautam,Marcos Girala,Adrià Juanola,Jeong Han Kim,Tae Hun Kim,Pramod Kumar,Barbara Lattanzi,Tae Hee Lee,Cosmas A. Rinaldi Lesmana,Richard Moreau,Preetam Nath,Gustavo Navarro,Ji Won Park,Gisela Pinero,Nikolaos Pyrsopoulos,Sophie Restellini,Gustavo Romero,Marco Sacco,Tiago Sevá-Pereira,Macarena Simón-Talero,Do Seon Song,Ki Tae Suk,Hans Van Vlierberghe,Sun Young Yim,E.L. Yoon,Giacomo Zaccherini +70 more
TL;DR: Differences in the prevalence of MDR bacterial infections in different global regions indicate the need for different empirical antibiotic strategies in different continents and countries.
Journal ArticleDOI
The neglected hepatitis C virus genotypes 4, 5 and 6: an international consensus report.
Nabil Antaki,Antonio Craxì,Sanaa M. Kamal,Rami Moucari,Schalk Van der Merwe,Samir Haffar,Adrián Gadano,Nizar N. Zein,Ching-Lung Lai,Jean-Michel Pawlotsky,E. Jenny Heathcote,Geoffrey Dusheiko,Patrick Marcellin +12 more
TL;DR: Hepatitis C virus genotypes 4, 5 and 6 represent >20% of all HCV cases worldwide and are highly prevalent in sub‐Saharan Africa and in the Middle East, while HCV‐6 is found in Hong Kong, Vietnam, Thailand and Myanmar and also in American and Australian from Asian origin.